ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO732

Lupus Nephropathy: Clinical-Pathological Description of 400 Cases of the Colombian Caribbean Region and Variations in the Expression of Plasma MicroRNAs

Session Information

Category: Glomerular

  • 1004 Clinical/Diagnostic Renal Pathology and Lab Medicine


  • Aroca Martinez, Gustavo, Universidad Simón Bolívar, Barranquilla, Atlantico, Colombia
  • Domínguez, Alex, Universidad Simón Bolívar, Barranquilla, Atlantico, Colombia
  • Navarro, Elkin, Universidad Simon Bolivar, Barranquilla, Colombia
  • Gonzalez Torres, Henry J., Universidad Simon Bolivar, Barranquilla, Colombia
  • Silva, Diana, Universidad Simón Bolívar, Barranquilla, Atlantico, Colombia
  • Conde, Juan C., Clínica de la Costa, Barranquilla, Atlantico, Colombia
  • Almendrales, Lisneth, Universidad Simon Bolivar, Barranquilla, Colombia
  • Egea bermejo, Eduardo, Universidad del Norte, Barranquilla, Colombia
  • Iglesias Gamarra, Antonio, Universidad Nacional de Colombia, BOGOTA, Colombia

Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE). Renal biopsy allows diagnosing the histopathological classes of LN, however, it is an invasive technique associated with risk of hemorrhage. It is a priority to characterize noninvasive diagnostic tests and alterations in the differential expression of microRNAs (miRNAs) to measure LN activity. The objective was describe the clinical-pathological characteristics and to analyze the differential expression of a group of plasma miRNAs in patients with LN.


Retrospective analytical study. 400 patients are included with LN diagnosed by renal biopsy of the Caribbean Region between January 2008 and December 2016. Differentially expressed miRNAs were selected by Illumina and their diagnostic ability was validated by qPCR in 100 patients with LN.


400 patients, 86% were women. Average age of 37 ± 13.2 years. Mean follow-up time: 48 ± 20 months. Main syndromic diagnoses: nephritic syndrome (51%). Histological class: IV (70.7%), III (19.3%), II (6.5%). 234 (58%) patients did not achieve remission at 48 months. The miRNAs proposed as candidates were: miR-221-5p, miR-380-3p, miR-556-5p, miR-758-3p and miR-3074-3p, for their high sensitivity (97%) and specificity (70.3%); Positive predictive value (82.5%), negative predictive value (96%) and diagnostic efficacy (87.9%).


The miRNAs (miR-221-5p, miR-380-3p, miR-556-5p, miR-758-3p and miR-3074-3p) are possible diagnostic biomarkers and the differential expression pattern of miRNA would have significant implications in the pathophysiology of LN.